Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancer
New trial pairs zoldonrasib and daraxonrasib against chemotherapy in first-line metastatic pancreatic adenocarcinoma.
Revolution Medicines had one notable registry update this week, a newly posted Phase 3 study.
- Revolution Medicines' "RASolute 309" trial (NCT07805954) is a Phase 3, randomized, open-label study testing whether treatment with daraxonrasib plus zoldonrasib will improve progression-free survival and/or overall survival compared with standard gemcitabine and nab-paclitaxel when given as first-line treatment in patients with metastatic KRAS G12D-mutated pancreatic adenocarcinoma.1 The study is listed as recruiting, with an actual start date of 2026-08-281 and planned enrollment of 400 participants (estimated)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.